(133 days)
Not Found
No
The device description and intended use clearly describe a liquid wound cleanser that works through mechanical action. There is no mention of any computational or analytical capabilities, let alone AI/ML.
Yes
The device is intended for cleansing, moistening, debriding, and removal of foreign material from wounds, including various types of dermal lesions and burns, to allow for natural healing. These actions indicate a therapeutic purpose.
No
The device is a wound cleanser intended for cleansing, moistening, debriding, and removal of foreign material from wounds, not for diagnosing medical conditions.
No
The device description clearly states it is a "clear, colorless liquid" and is supplied in a "spray bottle with a plunger-activated pump applicator," indicating it is a physical product, not software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly describes the device as a wound cleanser and moistener applied directly to the skin and wounds. This is a topical application for managing external wounds.
- Device Description: The description reinforces this by stating it's a liquid sprayed onto the affected area and/or dressing for mechanical removal of debris and microorganisms.
- Lack of IVD Characteristics: An IVD device is used to examine specimens (like blood, urine, tissue) in vitro (outside the body) to provide information for diagnosis, monitoring, or screening. This device does not involve the analysis of biological specimens outside the body.
The device is a topical wound care product, not an in vitro diagnostic.
N/A
Intended Use / Indications for Use
NAWAlution for prescription use is intended for use under the supervision of healthcare professionals for cleansing, moistening, debriding, and removal of foreign material including microorganisms and debris from wounds, including acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, leg ulcers, diabetic foot ulcers, postsurgical wounds, first and second degree burns, grafted and donor sites. It is also intended for moistening absorbent wound dressings and cleaning minor burns, superficial abrasions and minor irritations of the skin.
NAWAlution for over-the-counter use is intended for cleansing wounds and moistening absorbent wound dressings for the management of minor cuts, abrasions, lacerations and minor burns.
Product codes
FRO
Device Description
The subject device of this submission is NAWAlution Skin and Wound Cleanser for prescription and OTC use. NAWAlution is a clear, colorless liquid intended for the management of wounds. The solution is applied by spraying it directly onto the affected area and/or the dressing. As a result of mechanical action of the solution moving across the wound bed foreign objects, foreign debris and exudate, including, dirt, debris, and microorganisms, are removed from the wound. Moistening and cleansing a wound, such as by using NAWAlution, allows for the natural healing process to take place. NAWAlution for prescription use is supplied in an 8 fluid oz. (237 mL) or 16 fluid oz. (473 mL) spray bottle with a plunger-activated pump applicator. NAWAlution for over-the-counter is supplied in a 50 mL (1.8 fluid oz.) spray bottle with a plunger-activated pump applicator. The solution contains cocamidopropylbetaine, hydrochloric acid, PHMB, zinc/iron, and purified water.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Wounds, including acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, venous ulcers, leg ulcers, diabetic foot ulcers, post-surgical wounds, first and second degree burns, grafted and donor sites. Minor cuts, abrasions, lacerations and minor burns.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Healthcare professionals for prescription use. Over-the-counter use.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The safety and effectiveness of NAWAlution is supported by biocompatibility testing, functional performance testing, and shelf-life testing conducted with the proposed device.
Key Metrics
Not Found
Predicate Device(s)
K113820, K131542, K072876, K110744, K042084
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
N/A
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
October 31, 2014
NAWA Heilmittel GmbH % Ms. Allyson B. Mullen Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, North West Washington, District of Columbia 20005
Re: K141660
Trade/Device Name: NAWAlution Regulatory Class: Unclassified Product Code: FRO Dated: October 6, 2014 Received: October 6, 2014
Dear Ms. Mullen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
David Krause -S
Binita S. Ashar, M.D., M.B.A., F.A.C.S. for Director
Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) To be determined
Device Name NAWAlution
Indications for Use (Describe)
NAW Alution for prescription use is intended for use under the supervision of healthcare professionals for cleansing, moistening, debriding, and removal of foreign material including microorganisms and debris from wounds, including acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, leg ulcers, diabetic foot ulcers, postsurgical wounds, first and second degree burns, grafted and donor sites. It is also intended for moistening absorbent wound dressings and cleaning minor burns, superficial abrasions and minor irritations of the skin.
NAWAlution for over-the-counter use is intended for cleansing wounds and moistening absorbent wound dressings for the management of minor cuts, abrasions, lacerations and minor burns.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
III.
NAWAlution
Submitter Name: | NAWA Heilmittel GmbH |
---|---|
Submitter Address: | Ostendstrasse 100 |
90482 Nuernberg | |
Germany | |
Contact Person: | Thomas Riesinger |
Phone Number: | 011-49-911-5444126 |
Fax Number: | 011-49-911-5444111 |
Date Prepared: | June 20, 2014 |
Device Trade Name: | NAWAlution Skin and Wound Cleanser |
Device Common Name: | Dressing, Wound, Drug |
Product Code: | FRO |
Classification: | Unclassified |
Predicate Devices: | NeutroPhase Skin and Wound Cleanser, NovaBay |
Pharmaceuticals, Inc., K113820, Product Code FRO, | |
Unclassified | |
Predicate Devices: | NeutroPhase Skin and Wound Cleanser OTC, NovaBay |
Pharmaceuticals, Inc., K131542, Product Code FRO, | |
Unclassified | |
Predicate Devices: | Prontosan Wound Irrigation Solution, B. Braun Medical, |
Inc., K072876, Product Code FRO, Unclassified | |
Predicate Devices: | Prontosan Wound Irrigation Solution, B. Braun Medical, |
Inc., K110744, Product Code FRO, Unclassified | |
Predicate Devices: | BioDerm Wound Spray, BioDerm Sciences, Inc., K042084 |
Product Code FRO, Unclassified. | |
Device Description: | The subject device of this submission is NAWAlution Skin |
and Wound Cleanser for prescription and OTC use. |
4
NAWAlution is a clear, colorless liquid intended for the management of wounds. The solution is applied by spraying it directly onto the affected area and/or the dressing. As a result of mechanical action of the solution moving across the wound bed foreign objects, foreign debris and exudate, including, dirt, debris, and microorganisms, are removed from the wound. Moistening and cleansing a wound, such as by using NAWAlution, allows for the natural healing process to take place. NAWAlution for prescription use is supplied in an 8 fluid oz. (237 mL) or 16 fluid oz. (473 mL) spray bottle with a plunger-activated pump applicator. NAWAlution for over-the-counter is supplied in a 50 mL (1.8 fluid oz.) spray bottle with a plunger-activated pump applicator. The solution contains cocamidopropylbetaine, hydrochloric acid, PHMB, zinc/iron, and purified water. NAWAlution for prescription use is intended for use under Intended Use: the supervision of healthcare professionals for cleansing, moistening, debriding, and removal of foreign material including microorganisms and debris from wounds, including acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, venous ulcers, leg ulcers, diabetic foot ulcers, post-surgical wounds, first and second degree burns, grafted and donor sites. It is also intended for moistening absorbent wound dressings and cleaning minor cuts, minor burns, superficial abrasions and minor irritations of the skin. NAWAlution for over-the-counter use is intended for cleansing wounds and moistening absorbent wound dressings for the management of minor cuts, abrasions, lacerations and minor burns. Substantial Equivalence: The proposed device and the predicate devices have the identical intended use and similar indications for use and technological characteristics, as shown in Table I.1, below. The safety and effectiveness of NAWAlution is supported by biocompatibility testing, functional performance testing, and shelf-life testing conducted with the proposed device.
5
Feature Being Compared | PROPOSED DEVICE | PREDICATE DEVICE | PREDICATE DEVICE | PREDICATE DEVICE |
---|---|---|---|---|
NAWAlution Skin and | NeutroPhase Skin and | Prontosan Wound | BioDerm Wound Spray | |
Wound Cleanser | Wound Cleanser | Irrigation Solution | ||
Indications for Use (Rx) | NAWAlution is intended for | |||
use under the supervision of | ||||
healthcare professionals for | ||||
cleansing, moistening, | ||||
debriding, and removal of | ||||
foreign material including | ||||
microorganisms and debris | ||||
from wounds, including acute | ||||
and chronic dermal lesions, | ||||
such as Stage I-IV pressure | ||||
ulcers, venous ulcers, leg | ||||
ulcers, diabetic foot ulcers, | ||||
post-surgical wounds, first | ||||
and second degree burns, | ||||
grafted and donor sites. It is | ||||
also intended for moistening | ||||
absorbent wound dressings | ||||
and cleaning minor cuts, | ||||
minor burns, superficial | ||||
abrasions and minor | ||||
irritations of the skin. | K113820: NeutroPhase Skin | |||
and Wound Cleanser is | ||||
intended for use under the | ||||
supervision of healthcare | ||||
professionals for cleansing | ||||
and removal of foreign | ||||
material including | ||||
microorganisms and debris | ||||
from wounds and for | ||||
moistening absorbent wound | ||||
dressings and cleaning minor | ||||
cuts, minor burns, superficial | ||||
abrasions and minor | ||||
irritations of the skin. It is | ||||
also intended for moistening | ||||
and debriding acute and | ||||
chronic dermal lesions, such | ||||
as Stage I-IV pressure ulcers, | ||||
stasis ulcers, leg ulcers, | ||||
diabetic foot ulcers, post- | ||||
surgical wounds, first and | ||||
second degree burns, grafted | ||||
and donor sites. | K072876: Prontosan Wound | |||
Irrigation Solution is intended | ||||
for prescription use is | ||||
intended for cleaning wounds | ||||
and for moistening and | ||||
lubricating absorbent wound | ||||
dressings for ulcers, burns, | ||||
post-surgical wounds and | ||||
abrasions. | K042084: BioDerm Sciences | |||
Wound Spray is intended to | ||||
cleanse, rinse and externally | ||||
manage dermal lesions such | ||||
as lacerations, post-operative | ||||
(surgical) wounds, partial and | ||||
full-thickness wounds, burns | ||||
and ulcers (diabetic, venous | ||||
stasis, pressure). It may also | ||||
be | ||||
used in conjunction with a | ||||
dressing that absorbs fluids | ||||
(i.e. gauze, gel, alginate, | ||||
foam, | ||||
hydrocolloid). | ||||
Feature Being Compared | PROPOSED DEVICE | PREDICATE DEVICE | PREDICATE DEVICE | PREDICATE DEVICE |
NAWAlution Skin and | NeutroPhase Skin and | Prontosan Wound | BioDerm Wound Spray | |
Wound Cleanser | Wound Cleanser | Irrigation Solution | ||
Indications for Use (OTC) | NAWAlution Skin and | K131542: NeutroPhase Skin | K110744: Prontosan Wound | K042084: BioDern Sciences |
Wound Cleanser for over- | and Wound Cleanser OTC is | Irrigation Solution for over- | Wound Spray is intended to | |
the-counter use is intended | intended for the management | the-counter use, is intended | clean, rinse and externally | |
for cleansing wounds and | of skin abrasions, lacerations, | for cleansing wounds and | manage skin | |
moistening absorbent wound | minor irritations, cuts, and | moistening absorbent wound | wounds such as minor | |
dressings for the management | intact skin. | dressings for the management | lacerations, minor cuts, minor | |
of minor cuts, abrasions, | of minor cuts, abrasions, | burns and abrasions. | ||
lacerations and minor burns. | lacerations and minor burns. | |||
Biocompatibility | Biocompatible | Biocompatible | Biocompatible | Biocompatible |
Appearance | Clear, colorless solution | Colorless | Clear, colorless | Clear, colorless solution |
Application method | Spray bottle (50 mL (1.8 | |||
fluid oz.) - OTC); | ||||
Spray bottle (8 fluid oz. (237 | ||||
mL) or 16 fluid oz. (473 mL) | ||||
– Rx) | Spray bottle (40 mL) | Tube applicator (40 mL); | ||
Squeeze bottle (350 mL) | Spray bottle (100 mL) | |||
Characteristics | Aqueous | Aqueous | Aqueous | Aqueous |
Density | ||||
(at 20°C) | 0.9 - 1 g/ml | ~ 1.0 g/ml | ~ 1.0 g/ml | 0.990 - 1.000 g/ml |
Materials | Purified water, | |||
Cocamidopropylbetaine, Zinc | ||||
Chloride, PHMB, | ||||
Hydrochloric acid, Trace | ||||
Element | Purified water, Sodium | |||
Chloride, Sodium | ||||
Hypochlorite | Purified water, PHMB, | |||
Undecylenamidopropyl | ||||
Betaine | Purified water, Zinc Chloride, | |||
Sulfuric Acid, Trace | ||||
Elements | ||||
Buffer | Not buffered | Not buffered | Not buffered | Not buffered |
Feature Being Compared | PROPOSED DEVICE | |||
NAWAlution Skin and | ||||
Wound Cleanser | PREDICATE DEVICE | |||
NeutroPhase Skin and | ||||
Wound Cleanser | PREDICATE DEVICE | |||
Prontosan Wound | ||||
Irrigation Solution | PREDICATE DEVICE | |||
BioDerm Wound Spray | ||||
Sterility | Non-sterile | Non-sterile | Sterile | Non-sterile |
Table III.1. Proposed and Predicate Device Comparison Matrix
6
7